C3i (Centre for Commercialization of Cancer Immunotherapy)
The Centre for Commercialization of Cancer Immunotherapy (C3i), located in Montreal, Canada, is a unique entity created in early 2016 with the ultimate goal to accelerate access for Canadians to innovative cancer immunotherapies and related fields including regenerative medicine, cellular therapy and gene therapy. Cancer Immunotherapy (CI) is revolutionizing cancer care by bringing novel and efficacious approaches with unprecedented curative potential. CI is changing the landscape of drug discovery and development, as well as that of diagnostic products. Indeed it has become a major focus of resources for global pharmaceutical companies, and for biotechnology companies, all of which are seeking to position themselves as major players. Expectations are high: according to the Leerink Partners firm, the CI market could reach globally 40 billion dollars by 2025.
Our vision is to be Canada’s catalyst for cancer immunotherapy and regenerative medecine business development. C3i will be the only Canadian immunotherapy development organisation that will lead to the clinical implementation and to the commercialization of these new therapeutic methods. To this end, we propose a novel business model combining direct patient clinical diagnostics using new genomic technologies, good manufacturing practices (GMP) standards and rapid access to clinical trials and regulatory support.
The combined clinical expertise of the Maisonneuve Rosemont Hospital along with the R&D and technical expertise of the Center of Excellence in Cellular Therapy (CETC) will drastically reduce the complexity of cell and gene therapeutics development. As our installations are fully operational and validated (satisfying both EMEA and FDA expectations), this will allow for the production of internationally sought-after products. Such an entity will not only reduce Canadian researcher reliance on US facilities to perform large scale clinical trials, but create a regional cluster of excellence that will retain Canadian researchers while attracting industry investments. Indeed, the clinical work environment we propose will allow for the clear identification of unmet medical needs and potential hurdles to accessibility, which is highly needed and sought after in current drug development strategies.